MANDARIN (S6371)
← catalyst calendarSponsored by Boston Scientific Corporation (industry) · BSX — their whole pipeline →.
Phase
Phase 3
Status
Completed
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
92actual
Sites
1
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-09-13 | actual | When the study began enrolling |
| Primary completion | 2026-02-13 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-08-10 | actual | The whole study's end, after follow-up |
| First posted | 2021-08-23 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Inoperable Hepatocellular Carcinoma
Interventions
- Combination product: TheraSphere™ Yttrium-90 Glass Microspheres
- Procedure: conventional Transarterial Chemoembolization(cTACE)
Primary outcomes
what the primary-completion date above is the date OFTime to progression (TTP)
measured through study completion, an average of 18 months
Safety assessed within 60 days post treatment using NCI-CTCAE v5.0
measured within 60 days post treatment
Permalink · BSX's whole pipeline · Catalyst calendar · Every registered study · What changed